Asset Details
Do you wish to reserve the book?
Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches
Do you wish to request the book?
Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches
2026
Overview
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disorder of the pilosebaceous unit, characterized by nodules, abscesses, and sinus tracts formation in apocrine gland-bearing skin. Increasing evidence suggests that HS is not solely a localized dermatological condition, but part of a broader systemic inflammatory state closely associated with metabolic dysfunction. Meta-inflammation, defined as a chronic, low-grade inflammatory response driven by metabolic imbalance, has emerged as a key mechanism linking obesity, insulin resistance, and immune dysregulation to the pathogenesis and progression of HS. It has indeed been demonstrated in numerous studies that HS and metabolic syndrome (MetS) share a core link through meta-inflammation, driven by common pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6. These pathways, along with insulin resistance and obesity-related adipose tissue dysfunction, drive both skin disease severity and metabolic comorbidities often creating a self-perpetuating cycle of inflammation and tissue damage. Understanding the interplay between meta-inflammation and HS provides important insights into disease heterogeneity and highlights the need for a multidisciplinary therapeutic approach. Targeting meta-inflammation through lifestyle interventions, weight management, and immuno-metabolic therapies may complement established treatments and improve clinical outcomes. In this review, we explore the pathogenic link between meta-inflammation and HS and discuss the therapeutic targets arising from this intricate interplay.
Publisher
Frontiers Media SA,Frontiers Media S.A
